StockNews.com assumed coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Free Report) in a research note published on Saturday. The firm issued a hold rating on the biotechnology company’s stock.
Just eight months after undergoing robotic surgery to remove his cancerous prostate, Mark Cwiek, a 70-year-old track and ...
Two Cork dairy farmers share their experience as volunteer drivers for patients receiving cancer treatment with the charity ...
A new study from Edith Cowan University reveals that regular exercise can reduce the recurrence rates of breast cancer by ...